Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A. Kornek B, et al. Among authors: vass k. JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923. JAMA Neurol. 2013. PMID: 23420110
Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients.
Schmied MC, Zehetmayer S, Reindl M, Ehling R, Bajer-Kornek B, Leutmezer F, Zebenholzer K, Hotzy C, Lichtner P, Meitinger T, Wichmann HE, Illig T, Gieger C, Huber K, Khalil M, Fuchs S, Schmidt H, Auff E, Kristoferitsch W, Fazekas F, Berger T, Vass K, Zimprich A. Schmied MC, et al. Among authors: vass k. Neurogenetics. 2012 May;13(2):181-7. doi: 10.1007/s10048-012-0316-y. Epub 2012 Mar 14. Neurogenetics. 2012. PMID: 22411505
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. Kuhle J, et al. Among authors: vass k. Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362898 Clinical Trial.
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, Enzinger C, Schiefermeier M, Schwarz C, Kornek B, Reindl M, Huber K, Grass R, Wimmer G, Vass K, Pfeiffer KH, Hartung HP, Schmidt R. Fazekas F, et al. Among authors: vass k. Neurology. 2001 Sep 11;57(5):853-7. doi: 10.1212/wnl.57.5.853. Neurology. 2001. PMID: 11552016 Clinical Trial.
Patient-reported quality of life in multiple sclerosis differs between cultures and countries: a cross-sectional Austrian-German-Polish study.
Pluta-Fuerst A, Petrovic K, Berger T, Fryze W, Fuchs S, Gold R, Kozubski W, Ladurner G, Petereit H, Potemkowski A, Rieckmann P, Sailer M, Szczudlik A, Vass K, Weber T, Zakrzewska-Pniewska B, Fazekas F. Pluta-Fuerst A, et al. Among authors: vass k. Mult Scler. 2011 Apr;17(4):478-86. doi: 10.1177/1352458510391341. Epub 2010 Dec 9. Mult Scler. 2011. PMID: 21148265
Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis.
Salhofer-Polanyi S, Windt J, Sumper H, Grill H, Essmeister M, Diermayr G, Zebenholzer K, Leutmezer F, Zulehner G, Vass K, Asenbaum-Nan S. Salhofer-Polanyi S, et al. Among authors: vass k. NeuroRehabilitation. 2013;33(2):285-92. doi: 10.3233/NRE-130956. NeuroRehabilitation. 2013. PMID: 23949063 Clinical Trial.
110 results